Acasti Pharma Inc

Acasti Pharma eyes phase III success with double data readout towards year-end

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) CEO Jan D'Alvise speaks to Proactive's Andrew Scott after announcing their second Phase III trial for the drug CaPre has reached 100% randomisation - which means the last patient's been accepted into the trial and randomised either onto the drug or a placebo.

The milestone means the firm remains on track to report topline results towards the end of the year.

CaPre to treat hypertriglyceridemia (high levels of triglycerides in the blood) which is known to contribute to heart disease.

Quick facts: Acasti Pharma Inc

Price: $2.87

Market: TSX-V
Market Cap: $243.43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...



Full interview: Acasti Pharma receives $750,000 grant from National Research...

Acasti Pharma (CVE: ACST) Co-founder COO and Chief Scientific Officer Dr, Pierre Lemieux joined Steve Darling from Proactive Vancouver on Skype to discuss the company has received a sizable grant from the Canadian Government to help their drug development work. Lemieux telling Proactive what...

1 week, 1 day ago

2 min read